tetano
Editor, Senior Moderator
J Microbiol Immunol Infect
. 2021 Apr 29;S1684-1182(21)00092-X.
doi: 10.1016/j.jmii.2021.04.002. Online ahead of print.
Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
Yu-Chi Kuo[SUP] 1 [/SUP], Chih-Cheng Lai[SUP] 2 [/SUP], Ya-Hui Wang[SUP] 3 [/SUP], Chao-Hsien Chen[SUP] 4 [/SUP], Cheng-Yi Wang[SUP] 5 [/SUP]
Affiliations
Abstract
Purpose: The aim of this meta-analysis is to compare the clinical efficacy and safety of baloxavir with other anti-influenza agents or placebo in the treatment of influenza.
Methods: PubMed, Embase, Web of Science, Google Scholar, Scopus, CINAHL, Cochrane databases and clinical registration were searched from inception until February 15 2021 for relevant randomized controlled trials (RCTs). Only phase 3 RCTs evaluating the usefulness of baloxavir in the treatment of influenza were included.
Results: Three RCTs enrolling 3771 patients (baloxavir group, n = 1451; oseltamivir group, n = 1288; placebo group, n = 1032) were included. Compared with oseltamivir, baloxavir had an insignificantly shorter time to the alleviation of symptoms (mean difference [MD], -1.29 h; 95% CI, -6.80 to 4.21; I[SUP]2[/SUP] = 0%). In contrast, baloxavir had a significantly shorter time to the alleviation of symptoms than placebo (MD, -26.32 h; 95% CI, -33.78 to -18.86; I[SUP]2[/SUP] = 0%). Baloxavir was associated with a significant decline in influenza virus titers and viral RNA load compared to oseltamivir and placebo. Baloxavir was associated with a lower risk of any adverse events than oseltamivir (OR, 0.82; 95% CI, 0.69-0.98; I[SUP]2[/SUP] = 0%) and placebo (OR, 0.79; 95% CI, 0.66-0.96; I[SUP]2[/SUP] = 0%).
Conclusions: The findings of this meta-analysis suggested that baloxavir is superior to placebo in the treatment of influenza in both clinical outcome and virological response. Moreover, baloxavir was found to have a better virological response than oseltamivir and to be as effective as oseltamivir clinically. Compared with oseltamivir and placebo, baloxavir appears to be a relatively safe anti-influenza agent.
Keywords: Baloxavir; Influenza; Oseltamivir.
. 2021 Apr 29;S1684-1182(21)00092-X.
doi: 10.1016/j.jmii.2021.04.002. Online ahead of print.
Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
Yu-Chi Kuo[SUP] 1 [/SUP], Chih-Cheng Lai[SUP] 2 [/SUP], Ya-Hui Wang[SUP] 3 [/SUP], Chao-Hsien Chen[SUP] 4 [/SUP], Cheng-Yi Wang[SUP] 5 [/SUP]
Affiliations
- PMID: 34020891
- DOI: 10.1016/j.jmii.2021.04.002
Abstract
Purpose: The aim of this meta-analysis is to compare the clinical efficacy and safety of baloxavir with other anti-influenza agents or placebo in the treatment of influenza.
Methods: PubMed, Embase, Web of Science, Google Scholar, Scopus, CINAHL, Cochrane databases and clinical registration were searched from inception until February 15 2021 for relevant randomized controlled trials (RCTs). Only phase 3 RCTs evaluating the usefulness of baloxavir in the treatment of influenza were included.
Results: Three RCTs enrolling 3771 patients (baloxavir group, n = 1451; oseltamivir group, n = 1288; placebo group, n = 1032) were included. Compared with oseltamivir, baloxavir had an insignificantly shorter time to the alleviation of symptoms (mean difference [MD], -1.29 h; 95% CI, -6.80 to 4.21; I[SUP]2[/SUP] = 0%). In contrast, baloxavir had a significantly shorter time to the alleviation of symptoms than placebo (MD, -26.32 h; 95% CI, -33.78 to -18.86; I[SUP]2[/SUP] = 0%). Baloxavir was associated with a significant decline in influenza virus titers and viral RNA load compared to oseltamivir and placebo. Baloxavir was associated with a lower risk of any adverse events than oseltamivir (OR, 0.82; 95% CI, 0.69-0.98; I[SUP]2[/SUP] = 0%) and placebo (OR, 0.79; 95% CI, 0.66-0.96; I[SUP]2[/SUP] = 0%).
Conclusions: The findings of this meta-analysis suggested that baloxavir is superior to placebo in the treatment of influenza in both clinical outcome and virological response. Moreover, baloxavir was found to have a better virological response than oseltamivir and to be as effective as oseltamivir clinically. Compared with oseltamivir and placebo, baloxavir appears to be a relatively safe anti-influenza agent.
Keywords: Baloxavir; Influenza; Oseltamivir.